Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Reply to S. Sorscher.

Innocenti F, Ou FS, Qu X, Zemla T, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ, Kabbarah O.

J Clin Oncol. 2019 Jul 3:JCO1901366. doi: 10.1200/JCO.19.01366. [Epub ahead of print] No abstract available.

PMID:
31268798
2.

Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).

Lenz HJ, Ou FS, Venook AP, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Bertagnolli MM, Blanke CD, Zemla T, Qu X, Wirapati P, Tejpar S, Innocenti F, Kabbarah O.

J Clin Oncol. 2019 May 1:JCO1802258. doi: 10.1200/JCO.18.02258. [Epub ahead of print]

PMID:
31042420
3.

A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer.

Piskol R, Huw L, Sergin I, Kljin C, Modrusan Z, Kim D, Kljavin N, Tam R, Patel R, Burton J, Penuel E, Qu X, Koeppen H, Sumiyoshi T, de Sauvage F, Lackner MR, de Sousa E Melo F, Kabbarah O.

Clin Cancer Res. 2019 Jul 15;25(14):4431-4442. doi: 10.1158/1078-0432.CCR-18-3032. Epub 2019 Apr 19.

PMID:
31004000
4.

Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.

Innocenti F, Ou FS, Qu X, Zemla TJ, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ, Kabbarah O.

J Clin Oncol. 2019 May 10;37(14):1217-1227. doi: 10.1200/JCO.18.01798. Epub 2019 Mar 13.

PMID:
30865548
5.

A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types.

Wagle MC, Kirouac D, Klijn C, Liu B, Mahajan S, Junttila M, Moffat J, Merchant M, Huw L, Wongchenko M, Okrah K, Srinivasan S, Mounir Z, Sumiyoshi T, Haverty PM, Yauch RL, Yan Y, Kabbarah O, Hampton G, Amler L, Ramanujan S, Lackner MR, Huang SA.

NPJ Precis Oncol. 2018 Mar 7;2(1):7. doi: 10.1038/s41698-018-0051-4. eCollection 2018.

6.

Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers.

Kim D, Choi Y, Ireland J, Foreman O, Tam RN, Patel R, Schleifman EB, Motlhabi M, French D, Wong CV, Peters E, Molinero L, Raja R, Amler LC, Hampton GM, Lackner MR, Kabbarah O.

PLoS One. 2016 Nov 15;11(11):e0165856. doi: 10.1371/journal.pone.0165856. eCollection 2016.

7.

Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter.

Qu X, Sandmann T, Frierson H Jr, Fu L, Fuentes E, Walter K, Okrah K, Rumpel C, Moskaluk C, Lu S, Wang Y, Bourgon R, Penuel E, Pirzkall A, Amler L, Lackner MR, Tabernero J, Hampton GM, Kabbarah O.

Oncogene. 2016 Dec 15;35(50):6403-6415. doi: 10.1038/onc.2016.170. Epub 2016 Jun 6.

8.

Genomic landscape of metastatic colorectal cancer.

Haan JC, Labots M, Rausch C, Koopman M, Tol J, Mekenkamp LJ, van de Wiel MA, Israeli D, van Essen HF, van Grieken NC, Voorham QJ, Bosch LJ, Qu X, Kabbarah O, Verheul HM, Nagtegaal ID, Punt CJ, Ylstra B, Meijer GA.

Nat Commun. 2014 Nov 14;5:5457. doi: 10.1038/ncomms6457.

9.

Antibody-drug conjugates: an emerging modality for the treatment of cancer.

Leal M, Sapra P, Hurvitz SA, Senter P, Wahl A, Schutten M, Shah DK, Haddish-Berhane N, Kabbarah O.

Ann N Y Acad Sci. 2014 Aug;1321:41-54. doi: 10.1111/nyas.12499. Review.

PMID:
25123209
10.

Integrative genome comparison of primary and metastatic melanomas.

Kabbarah O, Nogueira C, Feng B, Nazarian RM, Bosenberg M, Wu M, Scott KL, Kwong LN, Xiao Y, Cordon-Cardo C, Granter SR, Ramaswamy S, Golub T, Duncan LM, Wagner SN, Brennan C, Chin L.

PLoS One. 2010 May 24;5(5):e10770. doi: 10.1371/journal.pone.0010770.

11.

GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer.

Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, Wu J, Dhakal S, Wu M, Chen S, Feinberg T, Huang J, Saci A, Widlund HR, Fisher DE, Xiao Y, Rimm DL, Protopopov A, Wong KK, Chin L.

Nature. 2009 Jun 25;459(7250):1085-90. doi: 10.1038/nature08109.

12.

Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers.

Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A, O'Neil J, Gutierrez A, Ivanova E, Perna I, Lin E, Mani V, Jiang S, McNamara K, Zaghlul S, Edkins S, Stevens C, Brennan C, Martin ES, Wiedemeyer R, Kabbarah O, Nogueira C, Histen G, Aster J, Mansour M, Duke V, Foroni L, Fielding AK, Goldstone AH, Rowe JM, Wang YA, Look AT, Stratton MR, Chin L, Futreal PA, DePinho RA.

Nature. 2007 Jun 21;447(7147):966-71. Epub 2007 May 21.

14.

Revealing the genomic heterogeneity of melanoma.

Kabbarah O, Chin L.

Cancer Cell. 2005 Dec;8(6):439-41. Review.

15.

Advances in malignant melanoma: genetic insights from mouse and man.

Kabbarah O, Chin L.

Front Biosci. 2006 Jan 1;11:928-42. Review.

PMID:
16146783
16.

Diethylstilbestrol effects and lymphomagenesis in Mlh1-deficient mice.

Kabbarah O, Sotelo AK, Mallon MA, Winkeler EL, Fan MY, Pfeifer JD, Shibata D, Gutmann DH, Goodfellow PJ.

Int J Cancer. 2005 Jul 1;115(4):666-9.

17.

A panel of repeat markers for detection of microsatellite instability in murine tumors.

Kabbarah O, Mallon MA, Pfeifer JD, Edelmann W, Kucherlapati R, Goodfellow PJ.

Mol Carcinog. 2003 Dec;38(4):155-9.

PMID:
14639654
18.

Mlh1 deficiency accelerates myeloid leukemogenesis in neurofibromatosis 1 (Nf1) heterozygous mice.

Gutmann DH, Winkeler E, Kabbarah O, Hedrick N, Dudley S, Goodfellow PJ, Liskay RM.

Oncogene. 2003 Jul 17;22(29):4581-5.

PMID:
12881715
19.

Expression profiling of mouse endometrial cancers microdissected from ethanol-fixed, paraffin-embedded tissues.

Kabbarah O, Pinto K, Mutch DG, Goodfellow PJ.

Am J Pathol. 2003 Mar;162(3):755-62.

Supplemental Content

Loading ...
Support Center